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ABSTRACT 
Objectives: To characterize the nature and dynamics of the neutralizing antibody 
(NAb) response and escape in chronically HIV-2 infected patients.  
Methods: Twenty-eight chronically infected adults were studied over a period of 1-4 
years. The neutralizing activity of plasma IgG antibodies against autologous and 
heterologous primary isolates was analyzed using a standard assay in TZM-bl cells. Co-
receptor usage was determined in GHOST cells. The sequence and predicted 3D-
structure of the C2V3C3 Env region were determined for all isolates.  
Results: Only 50% of the patients consistently produced IgG NAbs to autologous and 
contemporaneous virus isolates. In contrast, 96% of the patients produced IgG 
antibodies that neutralized at least two isolates of a panel of six heterologous R5 
isolates. Breadth and potency of the neutralizing antibodies were positively associated 
with the number of CD4
+
 T cells and with the titer and avidity of C2V3C3-specific 
binding IgG antibodies. X4 isolates were obtained only from late stage disease patients 
and were fully resistant to neutralization. The V3 loop of X4 viruses was longer, had a 
higher net charge and differed markedly in secondary structure compared to R5 viruses.  
Conclusions: Most HIV-2 patients infected with R5 isolates produce C2V3C3-specific 
neutralizing antibodies whose potency and breadth decreases as the disease progresses. 
Resistance to antibody neutralization occurs in late stage disease and is usually 
associated with X4 viral tropism and major changes in V3 sequence and conformation. 
Our studies support a model of HIV-2 pathogenesis in which the neutralizing antibodies 
play a central role and have clear implications for the vaccine field.  
 
Key words: HIV-2 infection; neutralizing antibodies and disease progression; X4 
tropism and resistance to neutralizing antibodies; C2V3C3 neutralizing domains. 
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Introduction 
In contrast to HIV-1 infected patients, the majority of HIV-2-infected individuals have 
low or absent viremia, reduced general immune activation, and generally exhibit a much 
slower rate of CD4 decline and disease progression [1-7].
 
Hence, HIV-2 infection is 
viewed as an example of how the human immune system can control HIV replication 
and disease progression. The control of virus replication in HIV-2 patients might be 
related to a more effective and preserved antiviral innate, cellular and humoral immune 
responses [8-10]. Unlike HIV-1, most chronically infected HIV-2 patients elicit the 
production of potent and broadly neutralizing antibodies suggesting that these 
antibodies might directly contribute to suppress virus replication and control disease 
progression [11-16]. However, the neutralizing antibody response has still not been 
documented in disease progressing patients with low CD4
+
 T cell counts and X4 
isolates. Data is also lacking on the longitudinal dynamics of the neutralizing antibody 
response within a single individual, on the nature and sequence of the neutralizing 
epitopes and on HIV-2 resistance to antibody neutralization. This information is crucial 
for vaccine production and to understand the impact of neutralizing antibodies in viral 
evolution and pathogenesis.  
The antibody specificities that mediate HIV-2 neutralization in vivo are still elusive. 
Using different methods, the V3 region in the envelope gp125 has been identified as a 
potent neutralizing domain by some investigators [12, 13, 17-21]. Other weakly 
neutralizing epitopes were identified in V1, V2, V4 and C5 regions as well as in the 
CD4-binding site in gp125 and in the COOH-terminal region of the gp41 ectodomain 
[12, 13, 18, 19, 22]. Recently we found that mice immunized with a C2V3C3 
recombinant polypeptide from a HIV-2 CCR5-using isolate produce potent neutralizing 
antibodies against R5 viruses but not against X4 viruses[23]. This suggested that the 
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C2V3C3 region comprises a potent neutralizing domain that is differently presented in 
the envelope complex of X4 and R5 viruses and established a new association between 
HIV-2 tropism and susceptibility to antibody neutralization. Whether this neutralizing 
domain is formed in natural HIV-2 infection and whether susceptibility to antibody 
neutralization in HIV-2 patients is related with virus tropism is still not known.  
The aims of this study were to characterize the evolution and dynamics of the NAb 
response (autologous and heterologous) and escape in chronically HIV-2 infected 
patient and identify neutralizing determinants in the envelope glycoproteins.  
 
Material and Methods 
Study population.  
Twenty eight HIV-2 patients attending different hospitals in Lisbon were analyzed in 
this study. The characteristics of the patients are shown in Table 1. Samples were 
collected 1-4 times per year over a four year period. HIV-2 viremia in the plasma was 
quantified with a quantitative-competitive reverse transcriptase-PCR assay as described 
elsewhere [24]. Ethical approval was obtained from Hospital Curry Cabral Ethics 
Committee ethics committee and each participant gave written informed consent before 
entry into the study. 
 
Purification and quantification of IgGs 
The serum samples were diluted (1:1 ratio) in 500 mM NaCl (binding buffer) and mixed 
with equal volume (200 µl) of protein G Sepharose
Tm
 4 Fast Flow (GE Healthcare 
Europe). The beads were washed three times with binding buffer and one time with 
phosphate buffered saline (PBS) and the antibodies were eluted with 200 µl of 100 mM 
glycine-HCl elution buffer (pH 2.7) for 30 s. The beads were then centrifuged for 30 s 
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and the acid-eluted solution containing IgG was quickly removed and placed into a 
separate tube containing 1 M Tris (pH 9.0) buffer to reach pH 7.0 to 7.4. IgG 
nephelometry Turbox kits (Orion Diagnostica’s Turbox plus, Finland) were used to 
evaluate the concentrations of IgG fractions, following the manufacturer’s instructions. 
 
Virus isolation and co-receptor usage  
Virus were isolated by co-culture of patient PBMCs with PBMCs from uninfected 
individuals as described elsewhere [25]. Co-receptor usage of the HIV-2 isolates was 
determined in GHOST cells expressing CD4 and CCR1, CCR2b, CCR3, CCR4, CCR5, 
CXCR4, Bonzo/STRL33 or BOB/GPR15. Virus replication in these cells was 
determined with an in-house enzyme-linked immunosorbent assay (ELISA) for 
detection of HIV-2/SIV antigen [26]. CCR5 and CXCR4 usage were confirmed by entry 
inhibition assays using the CCR5 antagonists Maraviroc and TK779 and the CXCR4 
antagonist AMD3100 as described elsewhere [27]. 
 
Neutralization assay  
The neutralizing activity of IgG antibodies against HIV-2 primary isolates was analyzed 
in quadruplicate using a luciferase reporter gene assay in TZM-bl cells as reported 
previously [23, 28, 29].  Briefly, the eluted IgG samples (concentrations tested ranged 
from 0.05 to 100 µg/ml) were mixed with 2 to 15 ng of HIV-2 isolates (autologous and 
heterologous). After 1 h incubation at 37°C the IgG-virus mixture was added to the 
cells. Forty-eight hours later, cells were lysed directly in the culture plate and 100 µl of 
ONE-Glo luciferase assay substrate reagent (Promega, Madison, USA) was added. 
Plates were immediately analyzed for luciferase activity on a luminometer. Neutralizing 
activity was displayed as the percent inhibition of viral infection (luciferase activity) at 
 7 
 
each antibody concentration compared to an antibody-negative control: percent 
inhibition = [1 - (luciferase with antibody/luciferase without antibody)] X 100. Fifty 
percent inhibitory concentrations (IC50) were calculated through a dose-response curve 
fit with nonlinear function (four-parameter logistic equations) using GraphPad Prism 
version 5.1 software (San Diego, CA).  
 
Homology modelling 
Protein structure coordinates of C2V3C3 patient sequences were produced with SWISS-
MODEL homology modelling server [30-32] in automated mode using as template the 
structure of an unliganded and fully-glycosylated SIV gp120 envelope glycoprotein 
(PDB file 2BF1) [33]. Secondary structure was assigned with DSSP [34, 35] and 
imported to the correspondent loaded structure within Pymol (The PyMOL Molecular 
Graphics System, Version 1.2r3pre, Schrödinger, LLC, http://www.pymol.org/pymol.) 
using in house built scripts, after which 3D- images of the superimposed closely related 
models where produced. 
 
Statistical analyses 
Statistical analyses were performed using GraphPad Prism version 5.01 (San Diego, 
CA) with a level of significance of 5%. The Mann Whitney U was used to compare 
means between variables. Contingency tables were analyzed with Fisher’s exact test. To 
study how two variables varied together, linear regression was performed and Spearman 
correlation coefficients were computed.  
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Results  
Plasma viremia is associated with lower CD4
+ 
T cell counts and X4 tropism  
Twenty eight chronically HIV-2 infected patients were studied between 2003 and 2006. 
Nineteen patients were on antiretroviral therapy with protease and/or reverse 
transcriptase inhibitors (Table 1). Viral load was undetectable (<200 HIV-2 RNA copies 
µl
-1
) throughout the study period in 24 patients; median viral load in the remaining 4 
patients that had a positive viral load on at least one occasion was 5,525 copies (range, 
484-160,559) (Table 1). Median number of CD4
+ 
T cells at study entry was 363 cells µl
-
1
 (range, 15-1523). The median number of CD4
+
 T cells was significantly higher in 
aviremic patients compared with viremic patients (440 cells µl
-1
, range 66-1,523 vs 63 
cells µl
-1
, range 15-342; P = 0.0127). 
Twenty-five new primary HIV-2 isolates were obtained from twelve patients. Eight 
patients harbored viruses that preferentially or exclusively used CCR5 whereas isolates 
from the remaining 4 patients preferentially or exclusively used CXCR4 (Table 1). Out 
of ten X4 isolates, three isolates from three different patients were able to use ≥ 5 co-
receptors whereas R5 isolates could use only one or two additional co-receptors (Table 
1). Patients infected with X4 isolates tended to have lower median number of CD4
+
 T 
cell counts than patients infected with R5 isolates but this did not reach statistical 
significance (median number of CD4
+
 T cells in patients harboring X4 isolates, 78 cells 
µl
-1
; range, 15-342 vs 270 cells µl
-1
; range, 43-615; P = 0.0868). Strikingly, however, all 
patients infected with X4 isolates had detectable viral load on at least one occasion 
whereas patients infected with R5 isolates were aviremic. These results revealed a 
significant association between plasma viremia and X4 tropism (P = 0.002).  
 
Antibody neutralization is related with disease stage and viral tropism  
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Autologous neutralization , employing IgG samples, was investigated in twelve HIV-2 
patients. Autologous NAb activity was found in six (50%) patients infected with R5 
isolates (Figure 1A). The autologous NAb activity was sustained over time (up to 4 
years in patient 20) in three patients that were followed longitudinally suggesting that 
their R5 isolates were unable to escape neutralization. Most patients produced NAbs 
with IC50 in the micromolar range (median IC50 = 3.91 µg/ml; range = 0.05-38.0 µg/ml). 
Patient 18 was the exception with IC50 in the nanomolar range (50 ng/ml) (Figure 1B). 
Of note, we found no autologous neutralizing activity in the four patients infected with 
X4 isolates (patients 10, 19, 27 and 28) as well as in two patients infected with R5 
isolates (patients 1 and 7) (Figure 1A).  
The neutralizing activity of plasma IgGs from 28 patient samples (one time point per 
patient, year 2003) was tested against 11 heterologous primary isolates, three X4 and 
eight R5. All X4 isolates (PT19-03, PT27-03 and PT28-03) and two R5 isolates (PT01-
03 and PT07-03) resisted neutralization with up to 100µg/ml of purified IgG. These 
isolates were named X4-resistant (X4-R) and R5-resistant (R5-R). With the exception 
of patient 28 that did not neutralize any of the isolates, all patients produced IgG 
antibodies that neutralized at least two out of six R5-sensitive isolates (R5-S) (Table 2). 
In total, of the 164 IgG/R5-S virus combinations only 26 (16%) were negative for 
neutralization. Remarkably, the majority of the patients (18/27; 68%) could neutralize 
all R5-S isolates. NAb IC50 range was 0.06-49.08 µg/ml indicating wide variability in 
the neutralizing response between patients and that some patients elicit very potent 
heterologous NAb responses (Table 2). A strong negative correlation was found 
between the breadth of response and median IC50 (Spearman rank, r = -0.7209; P 
<0.0001) (Figure 2A) indicating that the most potent neutralizing antibodies are also 
those with higher breadth.  Importantly, the number of CD4
+
 T cells was negatively 
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associated with median IC50 (Spearman rank, r = -0.155; P = 0.0279) and positively 
associated with breadth of neutralizing response (proportion of viruses neutralized) 
(Spearman rank, r = 0.5249; P = 0.0041) (Figures 2B and C). Thus, a sustained and 
potent autologous and heterologous NAb response targeting exclusively R5 isolates is 
found in most chronically infected HIV-2 patients. The breadth and potency of 
neutralizing antibodies decrease as HIV-2 disease progresses and X4 viruses emerging 
in late stage disease are fully resistant to antibody neutralization.  
 
The NAb response in HIV-2 patients is directed to the C2V3C3 envelope region 
Previously, we have shown that most of our patients produce high titers of IgG 
antibodies that bind to polypeptides comprising the C2V3C3 region  in envelope gp125 
(rpC2-C3 polypeptide) and the gp36 ectodomain (rgp36 polypeptide) [36]. To search 
for the envelope determinants of neutralization we have analyzed the association 
between the neutralizing and binding antibodies. Remarkably, a significant inverse 
association was found between the median IC50 of heterologous IgG NAbs and the titer 
(Spearman r = -0.4729, P = 0.0262) and avidity (Spearman r = -0.6136, P = 0.0024) of 
IgG antibodies binding to the rpC2-C3 polypeptide (Figure 3A). This association was 
not found for rgp36 binding antibodies (NAb IC50 vs IgG binding titer, Spearman r = -
0.3968, P = 0.0675; NAb IC50 vs IgG avidity, Spearman r = -0.3199, P = 0.1466) 
(Figure 3B). The results suggest that the IgG NAbs in HIV-2 patients target the 
C2V3C3 envelope region.  
 
V3 correlates of X4 tropism and neutralization resistance.  
To investigate the interplay between the NAb response and the evolution of virus 
isolates in each individual and to try to gain some insight into the molecular basis of 
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neutralization sensitivity and escape in HIV-2, the consensus C3V3C3 amino acid 
sequences of the patient isolates were aligned with the reference HIV-2ALI sequence 
(an R5 isolate) (Supplemental Digital Content 1). Clonal nucleotide sequences of these 
isolates were previously published in Borrego et al. [37]. The most interesting amino 
acid changes possibly associated with neutralizing susceptibility were found in the V3 
loop. NAb sensitive R5 isolates (R5-S) had a median V3 loop net charge of 7 (range, 6-
7) which was lower than the V3 loop charge of NAb resistant isolates (R5-R and X4-R) 
(median 9, range 8-11) (Supplemental Digital Content 2). In addition, all X4-R isolates 
had a 1-3 amino acid insertion at the tip of the V3 loop.  
To explore further the determinants of tropism and neutralization susceptibility in HIV-
2, the 3-D structure of C2V3C3 amino acid sequences from R5 and X4 isolates were 
determined by homology modelling using the structure of an unliganded SIV gp120 
envelope glycoprotein as template [33]. The V3 loops of X4-R isolates fit in two major 
structural motifs, a β-α-β motif with higher β-sheet content present in patients 10, 27 
and 28 and a helix-loop-helix motif with higher α-helix content present in patient 19 
(Supplemental Digital Contents 3 and 4). The V3 loops of R5-S isolates fit into two 
main motifs that were markedly different from those of X4-R isolates. One structural 
pattern present in patients 2, 18 and 20 was characterized by absence or low amounts of 
regular secondary structural elements; the other was characterized by a high percentage 
of extended β-strands (patients 6, 11 and 16) (Supplemental Digital Contents 4 and 5). 
However, V3 loop structures from neutralization resistant R5 isolates (patients 1 and 7) 
were similar to one of the structures found in R5-S isolates Supplemental Digital 
Contents 4 and 6).  
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Discussion   
In this study the autologous and heterologous neutralizing IgG antibody responses were 
investigated in 28 HIV-2 infected patients from Portugal followed for a period of 1-4 
years. Patients covered the full spectrum of disease, a significant proportion being 
severely immune compromised [19 (68%) patients had lower than 500 CD4
+
T cells µl
-1
; 
eight (29%) had lower than 200 CD4
+ 
T cellsµl
-1
]. While, as expected, most patients 
(8/12, 67%) harbored viruses that preferentially used CCR5, four (33%) patients 
harbored X4 isolates and plasma viral load was detectable only in these patients. 
Viremic patients with X4 viruses had a significantly lower number of CD4
+
 T cells 
compared with aviremic patients providing further support for the association between 
viral X4 tropism and HIV-2 disease progression [16, 38].  
Similar to other studies, most (68%) patients elicited potent neutralizing antibodies 
against the majority of R5 isolates (neutralization sensitive R5 isolates termed R5-S) 
[11-14]. This is a significantly higher proportion compared to chronic HIV-1 patients in 
which only 10-31% make such broad NAbs [39-42]. As shown here, the potent and 
broad neutralizing activity in the plasma of HIV-2 patients is essentially due to the IgG 
antibody fraction. Patients with the most potent neutralizing IgGs were also those with 
higher neutralizing breadth as found previously in HIV-1 subtype B infected individuals 
[43] and HIV-2 patients from Guinea Bissau [11]. Importantly, breadth and potency of 
the neutralizing antibodies were positively associated with the number of CD4
+
 T cells. 
Hence, CD4
+
 T cell depletion and disease progression leads to a significant decrease in 
neutralizing activity in HIV-2 infected patients.  This may be due to a selective decrease 
in NAb production or maturation associated with the expansion of regulatory CD4
+
 T 
cells [44] which negatively regulate B cell function [45-47].  
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Autologous neutralizing IgG antibody responses were found in half of the patients that 
were tested and this response was sustained over the years in some patients. Of note, 
one patient produced very potent autologous NAbs that inhibited viral replication at 
nanogram concentration (patient 18, IC50, 50 ng/ml). The results confirm that some 
chronic HIV-2 infected patients can elicit autologous neutralizing antibodies [13, 15, 
16] and demonstrate that this neutralizing activity is due to the IgG antibody fraction 
and can be very potent and sustained over the course of infection. This is in contrast to 
HIV-1 infection where autologous NAbs are undetectable in most chronically infected 
patients because the virus easily escapes neutralization by these antibodies during acute 
infection [40, 48-50]. Remarkably, however, a significant proportion (50%) of our 
patients could not produce neutralizing antibodies targeting their autologous and 
contemporaneous virus isolates. This was neither due to an intrinsic immune defect nor 
to low levels of antibody production since with one exception (patient 28) all patients 
elicited neutralizing antibodies against heterologous virus isolates. Rather, the results 
are consistent with effective virus escape from autologous antibody neutralization which 
has not been detected before in HIV-2 infected patients.  Importantly, most (4 of 6, 
67%) of the patients with evidence of resistance to autologous antibody neutralization 
were infected with CXCR4-using isolates. These isolates were also fully resistant to 
neutralization by heterologous IgGs. Thus, neutralization- resistance in HIV-2 isolates 
is strongly associated with X4 virus tropism. Assuming that these 4 patients were 
originally infected with R5 isolates, our results suggest that the selective pressure 
exerted by the neutralizing antibodies in HIV-2 patients’ favors the selection of 
neutralization resistant X4 isolates. This is in contrast to HIV-1 where X4 viruses are 
usually easier to neutralize than R5 viruses [51-53] and escape from antibody 
neutralization has only rarely been associated with changes in viral tropism [53-56]. The 
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association between X4 tropism and resistance to antibody neutralization hasn’t been 
detected previously because late stage disease HIV-2 patients with low CD4
+
 T cell 
counts and X4 viruses have not been enrolled in previous studies. It has however been 
observed in mice immunized with envelope antigens derived from an R5 HIV-2 isolate 
[23]. These mice were unable to elicit antibodies against X4 isolates. Our studies 
support a model of HIV-2 pathogenesis in which a significant decrease in the number of 
CD4
+
 T cells and selective expansion of regulatory T cells occurring after many years of 
infection leads to the production of less potent neutralizing antibodies which favors the 
emergence of neutralization escape mutants able to use CXCR4 and other alternative 
co-receptors and infect other cell types. These X4 viruses replicate faster and are more 
pathogenic and promote faster disease progression [16, 57].  
To try to identify the determinants of antibody neutralization in the HIV-2 envelope, we 
have first analyzed the nature of the association between the patient’s neutralizing 
antibodies and antibodies binding to recombinant polypeptides comprising the C2, V3 
and C3 regions (rpC2-C3) or the gp36 ectodomain (rgp36). Remarkably, a significant 
direct association was found between the potency of heterologous IgG NAbs and the 
titer and avidity of C2V3C3-specific binding IgG antibodies. These results suggest that 
the neutralizing IgG antibodies in HIV-2 patients are mostly directed to the C2V3C3 
region in gp125. It remains unclear whether C2V3C3-specific antibodies actually 
neutralize HIV-2 or simply represent a marker for other Env-specific neutralizing 
antibodies such as those that target V1, V2, V4, C5 and CD4-binding site in gp125 [12, 
13, 18, 19, 22]. However, the observation that mice immunized with the C2V3C3 
polypeptide elicit a potent and broadly neutralizing antibody response supports the 
former hypothesis that the C2V3C3 region is a potent neutralizing domain in HIV-2 
[23]. 
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To further investigate the molecular and structural determinants of neutralization 
sensitivity and resistance in the C2, V3 and C3 regions of HIV-2 we analyzed an 
extensive number of clonal sequences of the C2V3C3 region obtained from our patients. 
Neutralization resistant isolates (X4 isolates and two R5 isolates) had a higher charged 
V3 loop compared to neutralization sensitive R5 isolates. In addition, X4 isolates had a 
larger V3 loop due to a 1-3 amino acid insertion. The results confirm that the charge and 
size of the V3 loop are crucial determinants of CCR5 and CXCR4 use by HIV-2 [58]. 
More importantly, they suggest that resistance to antibody neutralization in X4 isolates 
is also determined by the charge and size of the V3 loop. Early studies have shown that 
amino acids FHSQ (V3 loop positions 315-318) and WCR (positions 329-331) in the 
HIV-2 V3 stem interact with one another to form a conformational neutralizing epitope 
[18, 19]. The 1-3 amino acid insertions found in the X4-R isolates were placed 
immediately after the FHSQ motif and may prevent the proper assembly of this epitope 
thereby conferring resistance to the V3-directed neutralizing antibodies.  
Alternative V3 conformations that may be responsible for the selective interactions with 
CCR5 or CXCR4 have been identified in HIV-1 [59]. HIV-1 escape from antibody 
neutralization is usually not related with cell tropism because the neutralizing antibodies 
that target the V3 region are able to bind to both V3 β hairpin conformations [59, 60]. 
We showed that the V3 loop structures of X4-R and R5-S HIV-2 primary isolates are 
markedly different which supports a direct role of V3 loop conformation in the different 
susceptibility of these viruses to antibody neutralization. Hence, in contrast to HIV-1, 
R5 to X4 transition in HIV-2 primary isolates seems to involve a significant change in 
V3 loop charge, size and conformation which might prevent efficient binding of the 
neutralizing antibodies that target this region.  
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In conclusion, most HIV-2 patients infected with R5 isolates produce C2V3C3-specific 
neutralizing antibodies whose potency and breadth decreases as the disease progresses. 
Resistance to antibody neutralization occurs in late stage disease and is associated with 
X4 viral tropism and major changes in V3 loop sequence and conformation. Our studies 
support a new model of HIV-2 pathogenesis in which the neutralizing antibodies play a 
central role and have clear implications for the vaccine field.  
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Figure legends 
Figure 1- Autologous IgG neutralizing activity in HIV-2 patients. A) Neutralizing 
activity, expressed in inhibition of viral infectivity, is shown against autologous and 
contemporaneous R5 [gray bars] or X4 isolates [pink bars] from each patient. An excess 
of IgG was used in this experiment (100 µg/ml). B) The median IC50 (in µg/ml) was 
determined for all IgG/virus pairs that gave a positive neutralization result as shown in 
panel A. 
Figure 2- Relationship between CD4
+
 T cell counts and potency and breadth of 
neutralizing antibodies (IgG fraction) in HIV-2 patients. A) Association between 
potency and breadth of heterologous neutralizing antibodies; B) Association between 
the number of CD4
+
 T cells and potency of neutralizing antibodies; C) Association 
between the number of CD4
+
 T cells and breadth of neutralizing antibodies. P and r 
values refer to the Spearman rank correlation test. A linear regression line is also shown. 
Figure 3- Relationship between neutralizing and binding antibody reactivity and avidity 
in HIV-2 infection. The potency (median IC50) of heterologous neutralizing antibodies 
(IgG fraction) was plotted as a function of binding IgG titer (black circles) and avidity 
(red circles) against polypeptides rpC2-C3 (panel A) and rgp36 (panel B). A linear 
regression line is shown. 
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Table 1- Characteristics of HIV-2-infected patients and virus isolates. 
Patient Sampling 
year 
CD4
+
 T 
cells per 
µl 
HIV-2 RNA 
copies per ml 
of plasma 
Antiretroviral 
therapy 
Major chemokine 
coreceptor usage 
(minor)† 
1 2003 308 <200 ddI, d4T, IDV R5 
2 2003 358 <200 AZT, 3TC,NFV R5 
3 2003 307 <200 AZT, 3TC, IDV na 
4 2003 240 <200 3TC, d4T, IDV R5 
5 2003 480 <200 AZT, ddC R5 
6 2003 615 <200 AZT, 3TC, IDV R5 (Bob, Bonzo) 
7 2003 144 <200 3TC, d4T, NFV R5 (R1) 
2005 43 <200 3TC, d4T, NFV R5 (Bonzo) 
8 2003 141 <200 AZT, 3TC, NFV na 
9 2003 226 <200 Combivir 
(3TC/AZT) 
na 
10 2003 48 160,559 ddI, AZT,SQV X4 (R5, R1, R2b, 
R3, R4, Bob, 
Bonzo) 
11 2003 66 <200 Drug naïve R5 (R1, Bob) 
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12 2003 851 <200 Drug naïve na 
13 2003 184 <200 AZT, 3TC, IDV R5 
14 2003 521 <200 Drug naïve na 
15 2003 897 <200 Drug naïve na 
16 2003 367 <200 Atripla 
(FTC/TDF/EFV) 
R5 (Bob, Bonzo) 
2004 270 <200 Atripla R5 (Bob, Bonzo) 
(FTC/TDF/EFV) 
17 2003 480 <200 AZT, 3TC na 
18 2003 437 <200 d4T, 3TC, LPV R5 (Bob, Bonzo) 
2004 400 <200 d4T, 3TC, LPV R5 (Bob, Bonzo) 
2005 60 <200 d4T, 3TC, LPV R5 (Bob, Bonzo) 
19 2003 78 <200 TDF, ABC, LPV X4 
2004 73 5,246 TDF, ABC, LPV X4 (R2b) 
2005 85 <200 TDF, ABC, LPV X4 (R1) 
2006 76 ND TDF, ABC, LPV X4 (Bonzo) 
20 2003 275 <200 AZT, 3TC, ddI R5 (Bob, Bonzo) 
2004 65 <200 AZT, 3TC, NFV R5 (Bob, Bonzo) 
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2005 122 <200 AZT, 3TC, NFV R5 (Bonzo) 
2006 172 ND AZT, 3TC, NFV R5 (Bob, Bonzo) 
21 2003 1523 <200 Drug naïve na 
22 2003 440 <200 Drug naïve na 
23 2003 1112 <200 Drug naïve na 
24 2003 478 <200 d4T, 3TC na 
25 2003 587 <200 Drug naïve na 
26 2003 1079 <200 Drug naïve na 
27 2003 15 <200 Drug naïve X4 
2004 ND 484 AZT, 3TC, NFV X4 (R5, R1, R2b, 
R3, R4, Bob) 
28 2003 342 5,804 AZT, 3TC, NFV X4 (R1) 
2004 265 4,792 AZT, 3TC, NFV X4 (R5, R1, R2b, 
R3) 
2005 212 ND AZT, 3TC, NFV X4 (R1) 
†, Tropism was determined based on p26 antigen production in GHOST/CD4+ cells 
expressing each of the indicated co-receptors. CCR5 and CXCR4 usage were confirmed 
by an entry inhibition assay in TZM-bl cells using the CCR5 antagonists Maraviroc and 
TK779 and the CXCR4 antagonist AMD3100; na, not applicable (virus was not 
isolated); ND, not done.; AZT, Zidovudine; ddI, didanosine; ddC, Zalcitabine; d4T, 
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Stavudine, 3TC, Lamivudine; FTC, Emtricitabine;  ABC, Abacavir; EFV, Efavirenz; 
NFV, Nelfinavir; SQV, Saquinavir; LPV, Lopinavir; IDV, Indinavir. 
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Table 2- Potency of IgG neutralizing activity of HIV-2 patients on a panel of six 
heterologous primary R5 isolates. 
Patient  
Neutralizing activity on heterologous primary HIV-2 
isolates [Inhibitory concentration (IC50), µg/ml] 
PT02.03 PT06.03 PT11.03 PT16.03 PT18.03 PT20.03 
1 1.18 3.19 29.11 >50 1.41 10.72 
2 - 25.89 11.35 18.81 1.01 3.46 
3 2.13 41.73 28.31 27.63 2.21 2.99 
4 1.43 22.8 18.62 23.26 0.33 3.86 
5 0.65 14.18 11.9 20.68 0.18 4.1 
6 1.84 - >50 >50 0.15 >50 
7 0.07 >50 >50 >50 0.75 >50 
8 12.46 24.62 17.18 >50 0.08 4.16 
9 10.85 32.13 26.32 45.28 0.46 8.75 
10 0.67 20.7 7.35 5.87 1.18 2.5 
11 2.68 42.04 - >50 >50 >50 
12 0.3 16.74 2.99 3.14 0.82 3.84 
13 0.75 40.52 4.71 >50 0.13 4.03 
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14 1.96 31.19 4.56 2.08 0.18 3.93 
15 2.17 24.81 1.78 47.58 0.2 1.22 
16 19.03 7.49 4.09 - 2.14 8.96 
17 4.14 44.43 9.2 11.44 0.23 1.68 
18 9.61 16.86 1.9 2.87 - 4.08 
19 0.39 13.88 >50 >50 >50 3.78 
20 2.79 33.14 >50 >50 14.93 - 
21 8.88 49.08 22 0.73 15.93 15.88 
22 1.05 38.28 7.89 1.76 0.37 5.24 
23 1.37 43.12 8.63 18.64 1.42 4.74 
24 0.81 12.07 8.98 2.37 0.06 3.74 
25 2.36 16.04 7.82 1.42 0.07 3.38 
26 1.33 15.96 4.86 1.98 0.07 1.37 
27 4.26 5.91 >50 >50 >50 8.7 
28 >50 >50 >50 >50 >50 >50 
Red, ≤0.1 µg /ml; orange, 0.1 to 1 µg /ml; yellow, 1 to 10 µg /ml; 
green, ≥10 µg /ml; and white, not neutralized at any concentration 
tested. 
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